Preoperative balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension led to successful anesthetic management for total hysterectomy under general anesthesia: a case report

Tomoko Ota, Kazumi Kawai, Tomoko Niihata and Hideki Fukuda

Abstract

Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a disease of obstructive pulmonary artery remodeling as a consequence of major vessel thromboembolism. Balloon pulmonary angioplasty (BPA) is an alternative treatment for patients with inoperable CTEPH. We report a case of CTEPH which improved following preoperative BPA intervention, allowing total hysterectomy to be performed.

Case presentation: A 48-year-old woman was transferred to our hospital to undergo total hysterectomy for endometrial cancer. She developed pulmonary embolism 7 months ago at another hospital, and a diagnosis of CTEPH was made based on multiple pulmonary emboli and pulmonary hypertension at our institute. Two BPA sessions for seven branches of the bilateral pulmonary arteries were conducted, resulting in a decrease of mean pulmonary artery pressure from 54 to 33 mmHg. Total hysterectomy was successfully performed under general anesthesia without any complications.

Conclusions: BPA could be effective for reducing PH in patients with CTEPH undergoing noncardiac surgery.

Keywords: Balloon pulmonary angioplasty, Chronic thromboembolic pulmonary hypertension, Pulmonary hypertension

Background

Chronic thromboembolic pulmonary hypertension (CTEPH) is defined as the persistence of thrombi and vascular remodeling in pulmonary circulation after an embolic event associated with a mean pulmonary artery pressure (mPAP) of ≥ 25 mmHg [1, 2]. Pulmonary endarterectomy (PEA) is the only established treatment for advanced CTEPH [2]. Recent reports have suggested that balloon pulmonary angioplasty (BPA) is an alternative therapy for inoperable patients with CTEPH [3, 4]. However, there are few reports on the effectiveness of preoperative BPA for CTEPH [5].

We present a patient with CTEPH who underwent preoperative BPA to improve severe pulmonary hypertension (PH) and thereby tolerated total hysterectomy under general anesthesia.

Written informed consent was obtained from the patient’s guardian for publication of this case report and accompanying images.
## Case presentation

A 48-year-old woman (height 165 cm, weight 67 kg) had been hospitalized for schizophrenia in a psychiatric hospital. She had been prescribed sultopride hydrochloride, risperidone, and zotepine. Seven months prior to surgery, she was found to have developed dyspnea and palpitation on exertion, and lower leg edema. Computed tomography (CT) revealed thrombi in the main trunk of the left pulmonary artery as well as in the peripheries of the bilateral pulmonary arteries, confirming the diagnosis of pulmonary embolism. Transthoracic echocardiography showed a dilated right ventricle (RV) with moderate tricuspid valve regurgitation (TR) and an estimated mPAP of 43 mmHg, indicating PH (Table 1). Anticoagulant therapy was started with apixaban.

Five months prior to surgery, anticoagulant therapy was discontinued because of irregular genital bleeding, but it was resumed 2 weeks subsequently because of the reappearance of pulmonary embolism symptoms. Six weeks prior to surgery, anticoagulant therapy was again temporarily discontinued as a result of increased genital bleeding. She was diagnosed with endometrial cancer, and total hysterectomy was scheduled.

Two weeks prior to surgery, she was transferred to our institution from the psychiatric hospital. Her vital parameters at admission were as follows: heart rate of 72 beats/min, blood pressure of 124/86 mmHg, and percutaneous oxygen saturation (SpO₂) of 92% under oxygen administration of 2 L/min. She had severe edema of the lower extremities and jugular vein distention. Transthoracic echocardiography showed a dilated RV with flattening of the interventricular septum and with moderate TR, in addition to an estimated mPAP of 54 mmHg, suggesting severe PH (Fig. 1a). The left ventricle (LV) appeared D-shaped with preserved systolic function and exhibited an ejection fraction of 66%. Although CT showed no emboli in the pulmonary trunk (Fig. 2a), multiple blood flow defects revealed by lung perfusion scan suggested multiple emboli in the distal pulmonary artery (Fig. 2b), leading to the diagnosis of CTEPH, and promoted physicians to perform BPA in order to decrease mPAP before surgery.

Two BPA sessions were performed for bilateral pulmonary arteries by interventional cardiologists in another expert institution over a span of 6 days. The first BPA for A1, A2, A3, and A9 was performed, and the second BPA for A8b, A10a, and A10b was performed under local anesthesia. After BPA, SpO₂ increased from 86 to 91%. Transthoracic echocardiography performed 2 days after the second BPA showed an improvement in the deformity of the LV and mild TR, and the estimated mPAP decreased to 33 mmHg (Fig. 1b). After the first BPA, warfarin was started and stopped the day before surgery, and preoperative bridging with heparin was initiated. We could not assess whether the subjective symptoms and exercise capacity of the patient improved after BPA, since she had stayed in bed all day because of depression in schizophrenia.

Total hysterectomy was performed 3 days after the second BPA. General anesthesia was selected because of the patient’s unstable mental status and perioperative anticoagulant therapy. Upon entering the operating room, her heart rate was 66 beats/min, blood pressure was 128/82 mmHg, and SpO₂ was 92% under oxygen administration of 2 L/min. General anesthesia was induced using midazolam 3 mg, continuous infusion of remifentanil 0.1 μg/kg/min, and fentanyl 200 μg. After administration of rocuronium 40 mg, tracheal intubation was performed. Anesthesia was maintained using desflurane 3–4% in a 45% oxygen–air mixture with continuous infusion of remifentanil 0.1–0.2 μg/kg/min. A pulmonary artery catheter (PAC) was inserted in the right internal jugular vein. Transesophageal echocardiography (TEE) showed RV enlargement with mild TR and shape distortion of the interventricular septum during systole.

Introducer sheaths were placed in the right femoral artery and vein to allow for venoarterial extracorporeal membrane oxygenation in preparation for pulmonary

| Table 1 | Data from transthoracic echocardiography studies |
|---------|------------------------------------------------|
|         | 7 months prior to surgery | 2 weeks prior to surgery | Day prior to surgery | 5 days after surgery |
|         | (at the onset of PE)       | (pre-BPA)                | (post-BPA)           |                      |
| LVEDd (mm) | 41.1                    | 36.6                    | 42.6                  | 43.6                 |
| Tricuspid regurgitation | moderate         | moderate                | mild ~ moderate       | mild                 |
| TRPG (mmHg) | 72                      | 95                      | 48                    | 40                   |
| Estimated mPAP (mmHg) | 43                      | 54                      | 33                    | 28                   |

PE = pulmonary embolism, BPA = balloon pulmonary angioplasty, LVEDd = left ventricular end-diastolic dimension, TRPG = tricuspid regurgitation pressure gradient, estimated mPAP = estimated mean pulmonary artery pressure.
hypertensive crisis. Hypoxia, hypercapnia, acidosis, hypothermia, and inadequate analgesia were avoided to prevent increase of pulmonary vascular resistance [6]. At 10 min after hysterectomy, the patient’s blood pressure decreased to 58/35 mmHg, with a pulmonary artery pressure (PAP) of 28/19 mmHg. TEE indicated that there was no observable change in the size of the RV and LV cavity with mild TR; therefore, we determined that the patient was not in a pulmonary hypertensive crisis. The cause of the temporary hypotension was unclear; however, it was restored rapidly after administration of a total of 12 mg ephedrine. Thereafter, values ranged 90–120/50–60 mmHg for blood pressure, 30–40 mmHg for mPAP, and 1.9–2.4 L/min/m² for cardiac index.

No vasopressor other than ephedrine was required. The operation time was 1 h and 36 min and blood loss was 88 g. Because of concerns about postoperative restlessness, the TEE probe, PAC, and introducer sheaths were removed before awakening. The patient was promptly awakened and the endotracheal tube was removed. Effective postoperative analgesia was achieved with intravenous patient-controlled analgesia using fentanyl. Postoperatively, the patient was managed in the general gynecology ward. On the fifth day after surgery, anticoagulant therapy was restarted with apixaban.

Transthoracic echocardiography showed mild TR, with an estimated mPAP of 28 mmHg and no worsening of PH (Table 1). The patient was transferred to the psychiatric hospital on the 19th day after surgery.

Discussion

CTEPH is a class of PH characterized by chronic obstruction of pulmonary arteries due to the formation of thrombi. Apart from other types of PH, PEA is the only established and potentially curative treatment for CTEPH [2]. BPA is an alternative therapy for those ineligible for PEA because of comorbidities, surgically inaccessible lesions, and residual or recurrent PH after PEA [3, 4, 7, 8]. BPA is usually performed by a catheter inserted from the right jugular or femoral vein under local anesthesia. Intraprocedural complications are perforation, dissection of the pulmonary artery, and pneumothorax related to jugular vein injury. Notably, we should be careful of reperfusion pulmonary injury occurring within 48 h after BPA with an incidence of 0.3–7% [9–13], resulting from mechanical injury caused by perforation of the pulmonary artery [7]. Although BPA is effective for decreasing mPAP by approximately 20 mmHg, and if successful, to below 30 mmHg [3, 4, 7], repeated procedures, usually for 3–6 times, are required [4, 7, 8]. Therefore, BPA is not an appropriate preoperative intervention for
emergency operations. Patients with contrast medium allergy or severe renal failure are not eligible. After BPA, mPAP was below 30 mmHg at follow-up of 425 days [3]. Our patient was not suitable for PEA because of the presence of lesion in the distal pulmonary arteries. After BPA, mPAP reduced from 54 to 33 mmHg and total hypertension was performed under general anesthesia without an increase of PAP.

BPA is an emerging alternative therapy that has been mainly developed in Japan and performed in specialized major centers; therefore, BPA is not yet widely known. Anesthesiologists should have better knowledge of BPA as a preoperative intervention for CTEPH, and they should recommend BPA to patients and surgeons as a preoperative option based on the patient’s condition and surgical procedure. The prognosis of CTEPH has been reported to be poor when mPAP is over 30 mmHg [14]. Although the degree of PH tolerable for surgery under general anesthesia is unknown, noncardiac surgery could be performed without any complications by reducing mPAP to 30 mmHg using BPA, which could in turn improve postoperative outcomes.

In conclusion, BPA has become a promising technique for the treatment of patients with CTEPH who are ineligible for PEA. BPA could be an effective preoperative option for reducing PH in patients with CTEPH undergoing noncardiac surgery.

Abbreviations
BPA: Balloon pulmonary angioplasty; CT: Computed tomography; CTEPH: Chronic thromboembolic pulmonary hypertension; L.V.: Left ventricle; mPAP: Mean pulmonary artery pressure; PAC: Pulmonary artery catheter; PAP: Pulmonary artery pressure; PEA: Pulmonary endarterectomy; PH: Pulmonary hypertension; RV: Right ventricle; SpO₂: Percutaneous oxygen saturation; TEE: Transesophageal echocardiography; TR: Tricuspid valve regurgitation

Acknowledgements
The authors thank Crimson Interactive Pvt. Ltd. (Ulatus, www.ulatus.jp) for their assistance in manuscript translation and editing.

Authors’ contributions
TO and KK participated in the anesthetic management. TO drafted the manuscript. KK revised the manuscript. All authors read and approved the final manuscript.

Funding
No funding

Availability of data and materials
Data relevant to this case report are not available for public access because of patient privacy concerns.

Ethics approval and consent to participate
Not applicable

Consent for publication
Written informed consent was obtained from the patient’s guardian for the publication of this case report and accompanying images.

Competing interests
The authors declare that they have no competing interests.

Received: 10 May 2020 Accepted: 7 July 2020
Published online: 17 July 2020

References
1. Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2011;364:351–60.
2. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 2016; 37(1):67–119.
3. Ogawa A, Satoh T, Fukuda T, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: results of a multicenter registry. Circ Cardiovasc Qual Outcomes. 2017;10:e004029.
4. Keshav M, Patrick DS, Sonja B, et al. Chronic thromboembolic pulmonary hypertension: emerging endovascular therapy. Cardiovasc Diagn Ther. 2018;8(3):272–8.
5. Watanabe K, Ito N, Ohata T, et al. Preoperative balloon pulmonary angioplasty enabled noncardiac surgery of a patient with chronic thromboembolic pulmonary hypertension. A case report. Medicine. 2019;98:e14807.
6. Pilkington SA, Taboada D, Martinez G. Pulmonary hypertension and its management in patients undergoing non-cardiac surgery. Anesthesia. 2015;70:56–70.
7. Ogawa A, Matsubara H. After dawn - balloon pulmonary angioplasty for patients with chronic thromboembolic pulmonary hypertension. Circ J. 2018;82:1222–30.
8. Lang I, Meyer BC, Ogo T, et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;26:150119.
9. Mizoguchi H, Ogawa A, Munemasa M, et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2012;5:748–55.
10. Kataoka M, Inami T, Hayashida K, et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2012;5:756–62.
11. Inami T, Kataoka M, Ando M, et al. A new era of therapeutic strategies for chronic thromboembolic pulmonary hypertension by two different interventional therapies: pulmonary endarterectomy and percutaneous transluminal pulmonary angioplasty. PLoS One. 2014;9:e94587.
12. Andreasen AK, Ragnarsson A, Gude E, et al. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Heart. 2013;99:1415–20.
13. Ogo T, Fukuda T, Tsuji A, et al. Efficacy and safety of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension guided by cone-beam computed tomography and electrocardiogram-gated area detector computed tomography. Eur J Radiol. 2017;89:270–6.
14. Lewczuk J, Pizcko P, Jagas J, et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest. 2001;119:818–23.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.